Home›Golimumab›Golimumab + Rituximab

Does Golimumab Interact with Rituximab?

Golimumab and Rituximab have a major drug interaction according to U.S. FDA drug labeling data. A higher rate of serious infections has also been observed in RA patients treated with rituximab who received subsequent treatment with a TNF-blocker. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Golimumab Class
Tumor Necrosis Factor Blocker
Rituximab Class
CD20-directed Cytolytic Antibody
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Golimumab and your doctor is considering prescribing Rituximab (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Golimumab(Simponi)+💊 Rituximab(Rituxan Hycela)

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
Tumor Necrosis Factor Blocker
Drug B class
CD20-directed Cytolytic Antibody
Source
FDA drug label - golimumab

What this means in plain English

A higher rate of serious infections has also been observed in RA patients treated with rituximab who received subsequent treatment with a TNF-blocker.

About Golimumab and Rituximab

Golimumab is a Tumor Necrosis Factor Blocker, while Rituximab is a CD20-directed Cytolytic Antibody. You may recognize them by the brand names Simponi and Rituxan Hycela. Golimumab is given by injection under the skin, whereas Rituximab is given by intravenous (IV) infusion. Both Golimumab and Rituximab carry an FDA boxed warning — the agency's most serious safety designation.

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Golimumab and Rituximab against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
Data integrity: Every interaction shown is extracted directly from official U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NIH) — no interactions are invented, inferred, or manually edited. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.